Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster Presentation at the American Association for the Study of

Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster
Presentation at the American Association for the Study of Liver Diseases
(AASLD) Annual Meeting

CAMBRIDGE, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals,
Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced a poster presentation featuring preclinical data for its uridine
nucleotide prodrug candidate for the treatment of hepatitis C virus (HCV)
infection at the 64th Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD), which will take place in Washington, DC, November
1-5, 2013. Full abstracts can now be viewed at the AASLD website at
www.aasld.org.

The following abstract will be presented in a poster session during the AASLD
Annual Meeting in the Poster Hall on Saturday, November 2, 2013, 2:00pm –
7:30pm Eastern Time:

  *Abstract No. 485: "A Novel Uridine Nucleotide Prodrug, IDX20963, and Its
    Potential for Use in a Low-Dose Direct-Acting Antiviral Regimen for HCV."

ABOUT HEPATITIS C

Hepatitis C virus is a common blood-borne pathogen infecting three to four
million people worldwide annually.The World Health Organization (WHO)
estimates that more than 170 million people worldwide are chronically infected
with HCV, representing a nearly 5-fold greater prevalence than human
immunodeficiency virus.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical Company engaged in the discovery and development of drugs
for the treatment of human viral diseases. Idenix's current focus is on the
treatment of patients with hepatitis C infection. For further information
about Idenix, please refer to www.idenix.com.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman, (617) 995-9807

Idenix Pharmaceuticals logo